Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT06652633

Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies

Led by Galapagos NV · Updated on 2026-02-05

546

Participants Needed

6

Research Sites

772 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a long-term follow-up study for participants treated with Galapagos (GLPG) CAR T-cell therapies to evaluate the long-term safety and efficacy of GLPG CAR T-cell products for 15 years post infusion. Per Health Authorities guidelines for gene therapy medicinal products that utilize integrating vectors (e.g. lentiviral vectors), long term safety and efficacy follow up of treated patients is required. The purpose of this study is to monitor all participants exposed to GLPG CAR T-cell therapies for 15 years following their last CAR T-cell infusion to assess the risk of delayed adverse events (AEs) and the long-term benefit/risk profile and to monitor for replication-competent lentivirus (RCL) and CAR-T cell persistence.

CONDITIONS

Official Title

Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants must have been treated with a Galapagos CAR T-cell therapy in a clinical trial or Managed Access Program
Not Eligible

You will not qualify if you...

  • There are no exclusion criteria for this study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 6 locations

1

Antwerp University Hospital

Edegem, Belgium, 2650

Actively Recruiting

2

Centre Hospitalier Universitaire (CHU) De Liège

Liège, Belgium, 4032

Actively Recruiting

3

Amsterdam UMC

Amsterdam, Netherlands, 1081 HV

Actively Recruiting

4

Academisch Medisch Centrum

Amsterdam, Netherlands, 1105 AZ

Actively Recruiting

5

Leids University Medical Center (LUMC)

Leiden, Netherlands, 2333 ZA

Actively Recruiting

6

Hospital Clinic De Barcelona

Barcelona, Spain, 08036

Actively Recruiting

Loading map...

Research Team

G

Galapagos Medical Information

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies | DecenTrialz